Ecstasy, a dangerous psychoactive drug, has become a popular recreational drug on college campuses and dance halls in the United States, United Kingdom, and around the world. No reports on ecstasy have shown addictiveness, and some users of ecstasy claim they prefer infrequent use which is not the usual addictive pattern. Jaw clenching, bruxism, and some cardiac arrhythmias requiring medical attention have been associated with consumption of ecstasy and some fatalities. In large scale retrospective questionnaire studies of subjective experiences users claimed that they felt a gentle relaxation and openness to others and few adversive effects. In rats and monkeys ecstasy has caused depletion of the neurotransmitter serotonin in the brain but similar effects have not been identified for humans. Case reports have shown panic attacks, flashbacks, paranoia, and even fatalities. The Drug Enforcement Administration in 1985 placed ecstasy in Schedule I, the most restrictive drug category.
Get full access to this article
View all access options for this article.
References
1.
BabergH. T.NelesenR. A.DimsdaleJ. E. (1996) Amphetamine use: return of an old scourge in a consultation psychiatry setting. American Journal of Psychiatry, 153, 789–793.
2.
BarnesD. M. (1988) New data intensify the agony over ecstasy. Science, 239, 864–868.
3.
BattagliaG.YehS. Y.DeSouzaE. G. (1988) MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacology Biochemistry and Behavior, 29, 269–274.
4.
BenazziF.MazzoliM. (1991) Psychiatric illness associated with “ecstasy”. Lancet, 338, 1520.
5.
BostR. O. (1988) 3.4-methylenedioxymethamphetamine (MDMA) and other amphetamine derivatives. Journal of Forensic Sciences, 33, 576–587.
6.
CohenR. S. (1995) Subjective reports on the effects of the MDMA (‘Ecstasy’) experience in humans. Progress in Neuropsychopharmacology and Biological Psychiatry, 19, 1137–1145.
7.
CohenR. S. (1996) Adverse symptomatology and suicide associates with the use of methylenedioxymethamphetamine (MDMA; “Ecstasy”). Biological Psychiatry, 39, 819–820.
8.
CohenR. S.CocoresJ. (1997) Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine. Progress in Neuropsychopharmacology and Biological Psychiatry, 21, 727–734.
9.
CreightonF. J.BlackD. L.HydeC. E. (1991) ‘Ecstasy’ psychosis and flashbacks. British Journal of Psychiatry, 159, 713–715.
10.
DowlingG. P.McDonoughE. T.BostR. O. (1987) ‘Eve’ and ‘Ecstasy’: a report of five deaths associated with the use of MDEA and MDMA. The Journal of the American Medical Association, 257, 1615–1617.
11.
ElkC. (1996) MDMA (Ecstasy): useful information for health professionals involved in drug education programs. Journal of Drug Education, 26, 349–350.
12.
GoldL. H.HubnerC. B.KoobG. F. (1989) A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology, 99, 40–47.
13.
Gouzoulis-MayfrankE.ThelenB.HabermeyerE.KunertH. J.KovarK. A.LindenblattH.HermleL.SpitzerM.SassH. (1999) Psychpathological, neuroendocrine and d-amphetamine in healthy volunteers. Psychopharmacology, 142, 41–50.
14.
GreerG.StrassmanR. J. (1985) Information on “Ecstasy”. American Journal of Psychiatry, 142, 1391. [letter]
15.
GrinspoonL.BakalarJ. B. (1986) Can drugs be used to enhance the psychotherapeutic process?American Journal of Psychotherapy, 40, 393–404.
16.
GrobC.BravoG.WalshR. (1990) Second thoughts on 3.4-methylenedioxymethamphetamine (MDMA) neurotoxicity (letter). Archives of General Psychiatry, 47, 288.
17.
GrobC. S.BravoG. L.WalshR. N.LiesterM. B. (1992) The MDMA-neurotoxicity controversy: implications for clinical research with novel psychoactive drugs. Journal of Nervous and Mental Disease, 180, 355–356.
18.
HenryJ. A.JeffreysK. J.DawlingS. (1992) Toxicity and deaths from 3.4-methylenedioxymethamphetamine (“ecstasy”). Lancet, 340, 384–387.
19.
KostenT. R.PriceL. H. (1992) Phenomenology and sequelae of 3, 4-methylenedioxymethamphetamine use. Journal of Nervous and Mental Disease, 180, 353–354.
20.
LiesterM. B.GrobC. S.BravoG. L.WalshR. N. (1992) Phenomenology and sequelae of 3, 4-methylenedioxymethamphetamine use. Journal of Nervous and Mental Disease, 180, 345–352.
21.
McCannU. D.RicaurteG. A. (1992) MDMA (“Ecstasy”) and panic disorder: induction by a single dose. Biological Psychiatry, 32, 950–953.
22.
McGuireP.FahyJ. (1991) Chronic paranoid psychosis after misuse of MDMA (“ecstasy”). British Medical Journal, 302, 697.
23.
MurrayJ. B. (1998) Psychophysiological aspects of amphetamine-methamphetamine abuse. The Journal of Psychology, 132, 227–237.
24.
NagelL.McDougallD.GranbyD. (1996) Students' self-reported substance abuse by grade level and gender. Journal of Drug Education, 26, 49–56.
PeroutkaS. J. (1987) Incidence of recreational use of 3.4-methylenedimethoxymethamphetamine (MDMA, “Ecstasy”) on an undergraduate campus. New England Journal of Medicine, 317, 1542–1543.
27.
PeroutkaS. J. (1989) ‘Ecstasy’: a human neurotoxin?Archives of General Psychiatry, 46, 191. [letter]
28.
RandallT. (1992) ‘Rave’ scene, ecstasy use, leap Atlantic. The Journal of the American Medical Association, 268, 1505.
29.
RicaurteG. A.DeLanneyL. E.IrwinI.LangstonJ. W. (1988) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Research, 446, 165–168.
30.
RicaurteG. A.FornoL. S.WilsonM. A.DelanneyL. E.IrwinI.MolliverM. E.LangstonJ. W. (1988) (+) 3.4-methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. The Journal of the American Medical Association, 260, 51–55.
31.
RothwellP. M.GrantR. (1993) Cerebral venous sinus thrombosis induced by ‘Ecstasy’. Journal of Neurology, Neurosurgery, and Psychiatry, 56, 1035.
SchmidtC. J. (1986) Neurotoxicity of the psychedelic amphetamine methylenedioxymethamphetamine. Journal of Pharmacology and Experimental Therapeutics, 240, 1–7.
34.
SchmidtC. J.WuL.LovenbergW. (1986) Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. European Journal of Pharmacology, 124, 175–178.
35.
ShulgunA. T. (1986) The background and chemistry of MDMA. Journal of Psychoactive Drugs, 18, 291–304.
36.
SolowijN.HallW.LeeN. (1992) Recreational MDMA in Sydney: a profile of “Ecstasy” users and their experience with the drug. British Journal of Addiction, 87, 1161–1178.
37.
Whitaker-AzmitiaP. M.AronsonT. A. (1989) “Ecstasy” (MDMA)-induced panic. American Journal of Psychiatry, 146, 119. [letter]
